Physiology of the aging bone and mechanisms of action of bisphosphonates

Biogerontology

Volumn 12, Issue 5, 2011, Pages 397-408

  Dominguez, Ligia J ^a   Bella, Giovanna Di ^a   Belvedere, Mario ^a   Barbagallo, Mario ^a  

^a UNIVERSITY OF PALERMO   (Italy)

Author keywords

Apoptosis; Bisphosphonate; Bone turnover; Osteoblast; Osteoclast; Osteocyte

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CLODRONIC ACID; ETIDRONIC ACID; FARNESYL PYROPHOSPHATE SYNTHASE; GLUCOCORTICOID; MEVALONIC ACID; MINODRONIC ACID; NERIDRONIC ACID; NITROGEN DERIVATIVE; OLPADRONIC ACID; PAMIDRONIC ACID; RISEDRONIC ACID; SYNTHETASE; TILUDRONIC ACID; UNCLASSIFIED DRUG; ZOLEDRONIC ACID;

AGING; APOPTOSIS; BINDING COMPETITION; BONE MATRIX; BONE MATURATION; BONE METASTASIS; BONE REMODELING; CALCIFICATION; CANCER CELL; CONFERENCE PAPER; CORTICOSTEROID INDUCED OSTEOPOROSIS; DRUG MECHANISM; DRUG POTENCY; ENZYME ACTIVE SITE; ENZYME SUBSTRATE COMPLEX; FRAGILITY FRACTURE; HUMAN; ISOPRENYLATION; METABOLITE; OSSIFICATION; OSTEOCLAST; OSTEOCYTE; OSTEOLYSIS; PAGET BONE DISEASE; POSTMENOPAUSE; PRIORITY JOURNAL; SENESCENCE;

AGING; BONE AND BONES; BONE DENSITY CONSERVATION AGENTS; BONE REMODELING; CELL AGING; DIPHOSPHONATES; FEMALE; HUMANS; MALE; OSTEOBLASTS;

EID: 83255191689     PISSN: 13895729     EISSN: 15736768     Source Type: Journal    
DOI: 10.1007/s10522-011-9344-5     Document Type: Conference Paper

References (74)

1. Almeida M, Ambrogini E, Han L, Manolagas SC, Jilka RL (2009) Increased lipid oxidation causes oxidative stress, increased PPAR{gamma} expression and diminished proosteogenic Wnt signaling in the skeleton. J Biol Chem 284:27438-27448
2. Bevilacqua M, Dominguez LJ, Rosini S, Barbagallo M (2005) Bisphosphonates and atherosclerosis: why? Lupus 14:773-779 (Pubitemid 41413310)
3. Boivin GY, Chavassieux PM, Santora AC, Yates J, Meunier PJ (2000) Alendronate increases bone strength by increasing the mean degree of mineralization of bone tissue in osteoporotic women. Bone 27:687-694
4. Bonewald LF (2007) Osteocytes as dynamic multifunctional cells. Ann NY Acad Sci 1116:281-290 (Pubitemid 350274320)
5. Bonewald LF, Johnson ML (2008) Osteocytes, mechanosensing and Wnt signaling. Bone 42:606-615
6. Boyle WJ, Simonet WS, Lacey DL (2003) Osteoclast differentiation and activation. Nature 423:337-342 (Pubitemid 40852708)
7. Bravenboer N, Papapoulos SE, Holzmann P, Hamdy NA, Netelenbos JC, Lips P (1999) Bone histomorphometric evaluation of pamidronate treatment in clinically manifest osteoporosis. Osteoporos Int 9:489-493 (Pubitemid 29348563)
8. Byrjalsen I, Leeming DJ, Qvist P, Christiansen C, Karsdal MA (2008) Bone turnover and bone collagen maturation in osteoporosis: effects of antiresorptive therapies. Osteoporos Int 19:339-348 (Pubitemid 351199183)
9. Chavassieux PM, Arlot ME, Reda C, Wei L, Yates AJ, Meunier PJ (1997) Histomorphometric assessment of the long-term effects of alendronate on bone quality and remodeling in patients with osteoporosis. J Clin Invest 100:1475-1480 (Pubitemid 27425772)
10. Coleman R (2011) The use of bisphosphonates in cancer treatment. Ann NY Acad Sci 1218:3-14
11. D'Aoust P, McCulloch CA, Tenenbaum HC, Lekic PC (2000) Etidronate (HEBP) promotes osteoblast differentiation and wound closure in rat calvaria. Cell Tissue Res 302:353-363
12. Ducy P, Schinke T, Karsenty G (2000) The osteoblast: a sophisticated fibroblast under central surveillance. Science 289:1501-1504
13. Dufresne TE, Chmielewski PA, Manhart MD, Johnson TD, Borah B (2003) Risedronate preserves bone architecture in early postmenopausal women in 1 year as measured by three-dimensional microcomputed tomography. Calcif Tissue Int 73:423-432 (Pubitemid 37466634)
14. Dunford JE, Thompson K, Coxon FP, Luckman SP, Hahn FM, Poulter CD, Ebetino FH, Rogers MJ (2001) Structureactivity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates. J Pharmacol Exp Ther 296:235-242 (Pubitemid 32112446)
15. Dunford JE, Rogers MJ, Ebetino FH, Phipps RJ, Coxon FP (2006) Inhibition of protein prenylation by bisphosphonates causes sustained activation of Rac, Cdc42, and Rho GTPases. J Bone Miner Res 21:684-694
16. Duque G (2008) Bone and fat connection in aging bone. Curr Opin Rheumatol 20:429-434
17. Duque G, Rivas D (2007) Alendronate has an anabolic effect on bone through the differentiation of mesenchymal stem cells. J Bone Miner Res 22:1603-1611 (Pubitemid 351229330)
18. Duque G, Li W, Adams M, Xu S, Phipps R (2011) Effects of risedronate on bone marrow adipocytes in postmenopausal women. Osteoporos Int 22:1547-1553
19. Ebetino FH, Roelofs A, Boyde A, Lundy M, McKenna C, Blazewska K, Sun S, Kashemirov B, Henneman Z, Nancollas G, Russell R, Rogers M, Coxon F (2009) Analyzing the skeletal distribution and cellular uptake of fluorescently-labeled bisphosphonate analogues in vivo. JBMR (ASBMR annual meeting):A09001962
20. Elmariah S, Delaney JAC, O'Brien KD, Budoff MJ, Vogel- Claussen J, Fuster V, Kronmal RA, Halperin JL (2010) Bisphosphonate use and prevalence of valvular and vascular calcification in women MESA (the multi-ethnic study of atherosclerosis). JACC 56:1752-1759
21. Fleisch H, Russell RG, Straumann F (1966) Effect of pyrophosphate on hydroxyapatite and its implications in calcium homeostasis. Nature 212:901-903
22. Fleisch H, Russell RG, Bisaz S, Casey PA, Muhlbauer RC (1968) The influence of pyrophosphate analogues (diphosphonates) on the precipitation and dissolution. Calcif Tissue Res:Suppl:10-10a
23. FleischH,RussellRG, FrancisMD(1969) Diphosphonates inhibit hydroxyapatite dissolution in vitro and bone resorption in tissue culture and in vivo. Science 165:1262-1264
24. Francis MD, Russell RG, Fleisch H (1969) Diphosphonates inhibit formation of calcium phosphate crystals in vitro and pathological calcification in vivo. Science 165:1264-1266
25. Garcia-Moreno C, Serrano S, Nacher M, Farre M, Diez A, Marinoso ML, Carbonell J, Mellibovsky L, Nogues X, Ballester J, Aubia J (1998) Effect of alendronate on cultured normal human osteoblasts. Bone 22:233-239 (Pubitemid 28127478)
26. Gasser AB, Morgan DB, Fleisch HA, Richelle LJ (1972) The influence of two diphosphonates on calcium metabolism in the rat. Clin Sci 43:31-45
27. Gimble JM, Zvonic S, Floyd ZE, Kassem M, Nuttall ME (2006) Playing with bone and fat. J Cell Biochem 98:251-266
28. Giuliani N, Pedrazzoni M, Negri G, Passeri G, Impicciatore M, Girasole G (1998) Bisphosphonates stimulate formation of osteoblast precursors and mineralized nodules in murine and human bone marrow cultures in vitro and promote early osteoblastogenesis in young and aged mice in vivo. Bone 22:455-461
29. Gnant M, Mlineritsch B, Schippinger W, Luschin-Ebengreuth G, Postlberger S, Menzel C, Jakesz R, Seifert M, Hubalek M, Bjelic-Radisic V, Samonigg H, Tausch C, Eidtmann H, Steger G, Kwasny W, Dubsky P, Fridrik M, Fitzal F, Stierer M, Rucklinger E, Greil R, Marth C (2009) Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N Engl J Med 360:679-691
30. Gourion-Arsiquaud S, Allen MR, Burr DB, Vashishth D, Tang SY, Boskey AL (2010) Bisphosphonate treatment modifies canine bone mineral and matrix properties and their heterogeneity. Bone 46:666-672
31. Guenther A, Gordon S, Tiemann M, Tiemann M, Burger R, Bakker F, Green JR, Baum W, Roelofs AJ, Rogers MJ, Gramatzki M (2010) The bisphosphonate zoledronic acid has antimyeloma activity in vivo by inhibition of protein prenylation. Int J Cancer 126:239-246
32. Hiraga T, Williams PJ, Ueda A, Tamura D, Yoneda T (2004) Zoledronic acid inhibits visceral metastases in the 4T1/luc mouse breast cancer model. Clin Cancer Res 10:4559-4567 (Pubitemid 38878900)
33. Idris AI, Rojas J, Greig IR, Van't Hof RJ, Ralston SH (2008) Aminobisphosphonates cause osteoblast apoptosis and inhibit bone nodule formation in vitro. Calcif Tissue Int 82:191-201
34. Jilka RL, Weinstein RS, Parfitt AM, Manolagas SC (2007) Quantifying osteoblast and osteocyte apoptosis: challenges and rewards. J Bone Miner Res 22:1492-1501 (Pubitemid 351229319)
35. Jung A, Mermillod B, Barras C, Baud M, Courvoisier B (1981) Inhibition by two diphosphonates of bone lysis in tumorconditioned media. Cancer Res 41:3233-3237 (Pubitemid 11035546)
36. Knothe Tate ML (2003) "Whither flows the fluid in bone?" An osteocyte's perspective. J Biomech 36:1409-1424 (Pubitemid 37120517)
37. Knothe Tate ML, Adamson JR, Tami AE, Bauer TW (2004) The osteocyte. Int J Biochem Cell Biol 36:1-8 (Pubitemid 37338467)
38. Lacey DL, Timms E, Tan HL, Kelley MJ, Dunstan CR, Burgess T, Elliott R, Colombero A, Elliott G, Scully S, Hsu H, Sullivan J, Hawkins N, Davy E, Capparelli C, Eli A, Qian YX, Kaufman S, Sarosi I, Shalhoub V, Senaldi G, Guo J, Delaney J, Boyle WJ (1998) Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 93:165-176 (Pubitemid 28180851)
39. Lehenkari PP, Kellinsalmi M, Napankangas JP, Ylitalo KV, Monkkonen J, Rogers MJ, Azhayev A, Vaananen HK, Hassinen IE (2002) Further insight into mechanism of action of clodronate: inhibition of mitochondrial ADP/ ATP translocase by a nonhydrolyzable, adenine-containing metabolite. Mol Pharmacol 61:1255-1262 (Pubitemid 34441791)
40. Luckman SP, Hughes DE, Coxon FP, Graham R, Russell G, Rogers MJ (1998) Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras. J Bone Miner Res 13:581-589 (Pubitemid 28163009)
41. Manolagas SC (2000) Birth and death of bone cells: basic regulatory mechanisms and implications for the pathogenesis and treatment of osteoporosis. Endocr Rev 21:115-137 (Pubitemid 32275592)
42. Manolagas SC, Parfitt AM (2010) What old means to bone. Trends Endocrinol Metab 21:369-374
43. Menschutkin M (1865) Ueber die Einwirkung des Chloracetyls auf phosphorige Säure. Ann Chem Pharm 133:317-320
44. Mitrofan LM, Castells FB, Pelkonen J, Monkkonen J (2010) Lysosomal-mitochondrial axis in zoledronic acid-induced apoptosis in human follicular lymphoma cells. J Biol Chem 285:1967-1979
45. Murshed M, Harmey D, Millan JL, McKee MD, Karsenty G (2005) Unique coexpression in osteoblasts of broadly expressed genes accounts for the spatial restriction of ECM mineralization to bone. Genes Dev 19:1093-1104 (Pubitemid 40632454)
46. Nancollas GH, Tang R, Phipps RJ, Henneman Z, Gulde S, Wu W, Mangood A, Russell RG, Ebetino FH (2006) Novel insights into actions of bisphosphonates on bone: differences in interactions with hydroxyapatite. Bone 38:617-627
47. Pan B, Farrugia AN, To LB, Findlay DM, Green J, Lynch K, Zannettino AC (2004) The nitrogen-containing bisphosphonate, zoledronic acid, influences RANKL expression in human osteoblast-like cells by activating TNF-alpha converting enzyme (TACE). J Bone Miner Res 19:147-154 (Pubitemid 41295147)
48. Passeri M, Baroni MC, Pedrazzoni M, Pioli G, Barbagallo M, Costi D, Biondi M, Girasole G, Arlunno B, Palummeri E (1991) Intermittent treatment with intravenous 4-amino-1- hydroxybutylidene-1, 1-bisphosphonate (AHBuBP) in the therapy of postmenopausal osteoporosis. Bone Miner 15:237-247
49. Paterson AH, Powles TJ, Kanis JA, McCloskey E, Hanson J, Ashley S (1993) Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer. J Clin Oncol 11:59-65 (Pubitemid 23059975)
50. Plotkin LI, Weinstein RS, Parfitt AM, Roberson PK, Manolagas SC, Bellido T (1999) Prevention of osteocyte and osteoblast apoptosis by bisphosphonates and calcitonin. J Clin Invest 104:1363-1374
51. Plotkin LI, Manolagas SC, Bellido T (2002) Transduction of cell survival signals by connexin-43 hemichannels. J Biol Chem 277:8648-8657 (Pubitemid 34968331)
52. Plotkin LI, Aguirre JI, Kousteni S, Manolagas SC, Bellido T (2005) Bisphosphonates and estrogens inhibit osteocyte apoptosis via distinct molecular mechanisms downstream of extracellular signal-regulated kinase activation. J Biol Chem 280:7317-7325 (Pubitemid 40341290)
53. Plotkin LI, Manolagas SC, Bellido T (2006) Dissociation of the pro-apoptotic effects of bisphosphonates on osteoclasts from their anti-apoptotic effects on osteoblasts/osteocytes with novel analogs. Bone 39:443-452 (Pubitemid 44164640)
54. Plotkin LI, Bivi N, Bellido T (2011) A bisphosphonate that does not affect osteoclasts prevents osteoblast and osteocyte apoptosis and the loss of bone strength induced by glucocorticoids in mice. Bone 49:122-127
55. Pollard M, Luckert PH (1985) Effects of dichloromethylene diphosphonate on the osteolytic and osteoplastic effects of rat prostate adenocarcinoma cells. J Natl Cancer Inst 75:949-954 (Pubitemid 16233972)
56. Qaseem A, Snow V, Shekelle P, Hopkins R Jr, Forciea MA, Owens DK (2008) Pharmacologic treatment of low bone density or osteoporosis to prevent fractures: a clinical practice guideline from the American College of Physicians. Ann Intern Med 149:404-415
57. Recker R, Masarachia P, Santora A, Howard T, Chavassieux P, Arlot M, Rodan G, Wehren L, Kimmel D (2005) Trabecular bone microarchitecture after alendronate treatment of osteoporotic women. Curr Med Res Opin 21:185-194 (Pubitemid 40469895)
58. Recker RR, Delmas PD, Halse J, Reid IR, Boonen S, Garcia- Hernandez PA, Supronik J, Lewiecki EM, Ochoa L, Miller P, Hu H, Mesenbrink P, Hartl F, Gasser J, Eriksen EF (2008) Effects of intravenous zoledronic acid once yearly on bone remodeling and bone structure. J Bone Miner Res 23:6-16
59. Reszka AA, Halasy-Nagy J, Rodan GA (2001) Nitrogen-bisphosphonates block retinoblastoma phosphorylation and cell growth by inhibiting the cholesterol biosynthetic pathway in a keratinocyte model for esophageal irritation. Mol Pharmacol 59:193-202 (Pubitemid 32108550)
60. Roelofs AJ, Coxon FP, Ebetino FH, Lundy MW, Henneman ZJ, Nancollas GH, Sun S, Blazewska KM, Bala JL, Kashemirov BA, Khalid AB, McKenna CE, Rogers MJ (2010) Fluorescent risedronate analogues reveal bisphosphonate uptake by bone marrow monocytes and localization around osteocytes in vivo. J Bone Miner Res 25:606-616
61. Rosen C (2008) Primer on the metabolic bone diseases and disorders of mineral metabolism, 7th edn. www.asbmrprimer.org. Accessed 16 Feb 2011
62. Rubin J, Rubin C, Jacobs CR (2006) Molecular pathways mediating mechanical signaling in bone. Gene 367:1-16 (Pubitemid 43286736)
63. Russell RG, Watts NB, Ebetino FH, Rogers MJ (2008) Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy. Osteoporos Int 19:733-759
64. Seeman E, Delmas PD (2006) Bone quality: the material and structural basis of bone strength and fragility. N Engl J Med 354:2250-2261
65. Sewing L, Steinberg F, Schmidt H, Goke R (2008) The bisphosphonate zoledronic acid inhibits the growth of HCT- 116 colon carcinoma cells and induces tumor cell apoptosis. Apoptosis 13:782-789
66. Silverman SL (2011) Bisphosphonate use in conditions other than osteoporosis. Ann NY Acad Sci 1218:33-37
67. Sugiyama T, Meakin LB, Galea GL, Jackson BF, Lanyon LE, Ebetino FH, Russell RGG, Price JS (2011) Risedronate does not reduce mechanical loading-related increases in cortical and trabecular bone mass in mice. Bone (in press)
68. Teitelbaum SL (2007) Osteoclasts: what do they do and how do they do it? Am J Pathol 170:427-435 (Pubitemid 47339379)
69. Theill LE, Boyle WJ, Penninger JM (2002) RANK-L and RANK: T cells, bone loss, and mammalian evolution. Annu Rev Immunol 20:795-823 (Pubitemid 34293440)
70. Udagawa N (2003) The mechanism of osteoclast differentiation from macrophages: possible roles of T lymphocytes in osteoclastogenesis. J Bone Miner Metab 21:337-343 (Pubitemid 38017689)
71. van Beek E, Lowik C, van der Pluijm G, Papapoulos S (1999) The role of geranylgeranylation in bone resorption and its suppression by bisphosphonates in fetal bone explants in vitro: a clue to the mechanism of action of nitrogencontaining bisphosphonates. J Bone Miner Res 14:722-729 (Pubitemid 29210598)
72. Varela I, Pereira S, Ugalde AP, Pereira S, Ugalde AP, Navarro CL, Suarez MF, Cau P, Cadinanos J, Osorio FG, Foray N, Cobo J, de Carlos F, Levy N, Freije JM, Lopez-Otin C (2008) Combined treatment with statins and aminobisphosphonates extends longevity in a mouse model of human premature aging. Nat Med 14:767-772
73. Viereck V, Emons G, Lauck V, Frosch KH, Blaschke S, Grundker C, Hofbauer LC (2002) Bisphosphonates pamidronate and zoledronic acid stimulate osteoprotegerin production by primary human osteoblasts. Biochem Biophys Res Commun 291:680-686 (Pubitemid 34687400)
74. Yasuda H, Shima N, Nakagawa N, Yamaguchi K, Kinosaki M, Mochizuki S, Tomoyasu A, Yano K, Goto M, Murakami A, Tsuda E, Morinaga T, Higashio K, Udagawa N, Takahashi N, Suda T (1998) Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci USA 95:3597-3602